Screener
Regeneron Pharmaceuticals REGN Reimbursement of commercialization-related expenses — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| (In millions) | Statement of Operations Classification | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|---|
| Regeneron's share of profits | Collaboration revenue | $2,032.6 | $1,282.1 | $3,483.4 | $2,300.2 |
| Reimbursement for manufacturing of commercial supplies | Collaboration revenue | $141.7 | $161.5 | $296.0 | $326.6 |
| Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses | (R&D expense) | $(19.4) | $(18.0) | $(36.1) | $(33.5) |
| Reimbursement of commercialization-related expenses | Reduction of SG&A expense | $188.8 | $194.0 | $372.9 | $353.2 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's reimbursement of commercialization-related expenses — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement of commercialization-related expenses — revenue of $188.8M in Q2 2026.
- How has Regeneron Pharmaceuticals's reimbursement of commercialization-related expenses — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement of commercialization-related expenses — revenue decreased by 2.7% year-over-year, from $194M to $188.8M.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement of commercialization-related expenses — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's reimbursement of commercialization-related expenses — revenue has grown at a 22.7% compound annual growth rate (CAGR), from $321.3M to $729.3M.
- What does reimbursement of commercialization-related expenses — revenue mean?
- This metric represents revenue recognized from the reimbursement of costs incurred by the company for commercializing products developed in collaboration with partners. It reflects the contractual recovery of shared marketing, sales, and distribution expenses from a collaboration partner. This line item is critical for understanding the net economic impact of shared-risk development and commercialization agreements.
Ask your AI about Regeneron Pharmaceuticals's reimbursement of commercialization-related expenses — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude